Skip to main content

Table 1 Demographics of 284 patients with metastatic angiosarcomas identified from SEER database between 2010 and 2016

From: Survival predictors of metastatic angiosarcomas: a surveillance, epidemiology, and end results program population-based retrospective study

Category N (%)
Age at diagnosis(years)
 ≤ 60 128(45.1%)
 > 60 156(54.9%)
 mean 60.5 Years
 median 63 Years
Gender
 Female 102(35.9%)
 Male 182(64.1%)
Race
 White 228(80.3%)
 Black 25(8.8%)
 Other 31(10.9%)
Year of diagnosis
 2010–2012 111(39.1%)
 2013–2014 86(30.3%)
 2015–2016 87(30.6%)
Metastatic sites at diagnosis
 Bone
  Yes 121(42.6%)
  No 163(57.4%)
 Brain
  Yes 26(9.2%)
  No 258(90.8%)
 Liver
  Yes 86(30.3%)
  No 198(69.7)
 Lung
  Yes 171(60.2%)
  No 113(39.8%)
Number of metastatic sites
 1 188(66.2%)
 ≥ 2 96(33.8%)
Grade
 I + II 6(2.1%)
 III 52(18.3%)
 IV 50(17.6%)
 Unknown 176(62.0%)
Size(cm)
 ≤ 10 110(38.7%)
 > 10 44(15.5%)
 Unknown 130(45.8%)
Treatment
 Chemotherapy
  Yes 145(51.1%)
  No 139(48.9%)
 RT
  Yes 66(23.2%)
  No 218(76.8%)
 ST
  Yes 83(29.2%)
  No 201(70.8%)
Dead
 Yes 253(89.1%)
 No 31(10.9%)
1-year OS rate 20.8%
3-year OS rate 3.8%
1-year CSS rate 22.0%
3-year CSS rate 5.2%
  1. Abbreviations: SEER Surveillance, Epidemiology, and End Results, OS overall survival, CSS cancer-specific survival, RT radiation treatment, ST surgery treatment